Stay updated with breaking news from Optimizing Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD, explore the significance of enrolling diverse patients in clinical trials and the pivotal role of community settings in advancing endometrial cancer research and treatment.
A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.
Explore the groundbreaking shift in frontline treatment for endometrial cancer, driven by recent data from trials like RUBY and GY018, highlighting the significant impact of checkpoint inhibitors in patients with mismatch repair deficiency.
Discover strategies for minimizing adverse events and overlapping toxicities in patients undergoing lenvatinib and pembrolizumab therapy for recurrent endometrial cancer.
Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.